Screening parameters for diagnosing primary aldosteronism in patients with moderate to severe obstructive sleep apnea hypopnea syndrome and resistant hypertension

Dien Yan, Xiaofan Zou, Xiao Li, Yue Hu, Hongbing He, Jianping Guo, Yulan Wang, Huanhuan Zheng, Jinxiang Fu, Meili Wang, Danping Peng, Xiaozi Zhou, Xian Luo, Jiahua Luo, Shaofen Li, Jinping Liu, Pingsheng Hu, Yunfeng ShenFrontiers in Cardiovascular Medicine 2024 · DOI

TL;DR

This study identifies optimal screening thresholds for primary aldosteronism (PA) in a high-risk patient group: those suffering from both resistant hypertension and moderate-to-severe sleep apnea. The researchers found that the aldosterone-renin ratio (ARR) is a potent screening tool in this population, but the "optimal" cutoff value should be adjusted based on the severity of the patient's sleep apnea to improve diagnostic accuracy.

What Problem Does This Paper Address?

Primary aldosteronism (PA)—a condition where the adrenal glands produce too much aldosterone—is a leading cause of secondary hypertension. It is particularly prevalent in patients with Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) and Resistant Hypertension (RH). These three conditions often form a "vicious cycle": PA leads to fluid retention and upper airway edema, worsening sleep apnea, while the intermittent hypoxia from sleep apnea triggers the renin-angiotensin-aldosterone system (RAAS), further elevating blood pressure.

Despite this known link, clinical guidelines lack definitive screening cutoff values specifically for patients with this "triple threat" of comorbidities. Standard thresholds may lead to high rates of false positives or missed diagnoses. This paper seeks to establish evidence-based cutoff values for the aldosterone-renin ratio (ARR) and plasma aldosterone concentration (PAC) to streamline PA diagnosis in these complex cases.

Methods

The researchers conducted a cross-sectional observational study at Ji’an Central Hospital in China, recruiting 241 patients diagnosed with both moderate-to-severe OSAHS and RH between 2020 and 2023.

The diagnostic workflow followed a standard but rigorous clinical path:

  1. Initial Screening: Measuring PAC, Plasma Renin Activity (PRA), and calculating the ARR.
  2. Confirmatory Testing: Patients with a positive ARR screening underwent the Saline Infusion Test (SIT) and the Captopril Challenge Test (CCT).
  3. Imaging & Subtyping: Adrenal CT scans were used to look for nodules, and a subset of patients underwent Adrenal Venous Sampling (AVS) to determine if the aldosterone excess was coming from one or both glands.
  4. Statistical Analysis: The team used Receiver Operating Characteristic (ROC) curves to determine the Area Under the Curve (AUC) and identify the optimal cutoff values that balanced sensitivity (catching true cases) and specificity (avoiding false alarms).

Datasets

The study utilized a primary clinical dataset of 241 patients (103 of whom had positive initial ARR screenings). From this cohort, 66 patients were ultimately confirmed to have PA. The dataset included detailed metrics such as the Apnea-Hypopnea Index (AHI), oxygen desaturation levels, and biochemical markers (triglycerides, creatinine, potassium).

Key Insights and Ideas

  • High Prevalence: Approximately 27% of patients with moderate-to-severe OSAHS and RH were diagnosed with PA. This is significantly higher than the prevalence in the general hypertensive population (3–13%), reinforcing the need for aggressive screening in this subgroup.
  • The Renin Limitation: While ARR and PAC were effective predictors, Plasma Renin Activity (PRA) alone had almost no predictive value (AUC = 0.51). This suggests that in the context of sleep apnea, looking at suppressed renin isn't enough; the ratio to aldosterone is critical.
  • Severity Matters: One of the most interesting findings was that the "optimal" threshold shifted with the severity of sleep apnea. For patients with severe OSAHS, the ARR was a much more accurate predictor (AUC 0.84) than for those with moderate OSAHS.
  • Pathophysiological Link: The authors suggest that aldosterone-induced volume overload contributes to OSAHS by promoting fluid shifts to the neck while the patient is supine, causing pharyngeal edema and airway obstruction.

Key Results

  • Optimal Cutoffs: For the entire group, the study identified an ARR cutoff of 45 (sensitivity 86%, specificity 52%) and a PAC cutoff of 17 (sensitivity 78%, specificity 55%) as the best balance for screening.
  • Differential Thresholds:
    • Moderate OSAHS: Optimal ARR cutoff was 45.
  • Severe OSAHS: Optimal ARR cutoff was lower, at 42, yielding a high sensitivity of 85% and a much improved specificity of 76%.
  • Diagnostic Accuracy: The ARR outperformed PAC as a screening tool, particularly in severe OSAHS cases, where it demonstrated significant predictive value for a definitive PA diagnosis.

Limitations and Future Work

  • Single-Center Study: The data comes from one hospital in China, which may limit the generalizability of the specific cutoff values to other ethnic groups or healthcare settings.
  • AVS Access: Adrenal Venous Sampling (the gold standard for subtyping PA) was only performed on patients who were willing to undergo surgery. This means some cases of bilateral adrenal hyperplasia might not have been as precisely categorized.
  • Bias: As a cross-sectional study, it can show correlation but cannot definitively prove the direction of causality between the worsening of OSAHS and the onset of PA.

The authors suggest that future multi-center research is needed to verify these thresholds across broader populations and to refine how severity-specific cutoffs can be integrated into international clinical guidelines.

Summary updated

Abstract

ARR and PAC are initial screening tools for PA, facilitating early detection, particularly in low-resource settings. In patients with OSAHS and RH, the ARR and PAC thresholds for PA diagnosis may require more stringent adjustment.
BibTeX
@inproceedings{yan2024screening,
  author = {Dien Yan and Xiaofan Zou and Xiao Li and Yue Hu and Hongbing He and Jianping Guo and Yulan Wang and Huanhuan Zheng and Jinxiang Fu and Meili Wang and Danping Peng and Xiaozi Zhou and Xian Luo and Jiahua Luo and Shaofen Li and Jinping Liu and Pingsheng Hu and Yunfeng Shen},
  title = {{Screening parameters for diagnosing primary aldosteronism in patients with moderate to severe obstructive sleep apnea hypopnea syndrome and resistant hypertension}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2024},
  doi = {10.3389/fcvm.2024.1383567},
}
Figure